SCHEMBL3770685

SCHEMBL3770685

O=C(O)c1ccc(-c2c[nH]c3ncc(-c4ccsc4)cc23)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 8/20 0.72
CAMKK2 Q96RR4 6/20 0.72
SGK1 O00141 3/20 0.72
CDK8 P49336 1/20 0.67
CHEK2 O96017 2/20 0.62
AAK1 Q2M2I8 1/20 0.56
MAP3K11 Q16584 1/20 0.56
CDK2 P24941 2/20 0.55
CCNT1 O60563 1/20 0.55
CCNA2 P20248 1/20 0.55
CDK9 P50750 1/20 0.55
DYRK1A Q13627 2/20 0.54
CLK1 P49759 1/20 0.54
DYRK2 Q92630 1/20 0.54
DYRK1B Q9Y463 1/20 0.54
CDC7 O00311 1/20 0.54
PLK4 O00444 1/20 0.54
CHEK1 O14757 1/20 0.54
AURKA O14965 1/20 0.54
MAPK13 O15264 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767902 0.90 MAP3K11 (0.70) AXLCAMKK2SGK1CDK8CHEK2
SCHEMBL3768633 0.88 AXL (0.92) AXLCAMKK2SGK1CDK8CHEK2
SCHEMBL15999481 0.87 CDK8 (0.58) AXLCAMKK2SGK1CDK8CHEK2
SCHEMBL3761982 0.85 DYRK1A (0.75) AXLCDK8CDK2CCNT1CCNA2
SCHEMBL3774587 0.84 AXL (1.00) AXLCAMKK2SGK1CDK8CHEK2
SCHEMBL3696023 0.83 CLK1 (0.72) AXLCAMKK2SGK1CDK8AAK1
SCHEMBL3767957 0.82 AXL (0.81) AXLCAMKK2SGK1CDK8MAP3K11
SCHEMBL3759528 0.82 AXL (0.81) AXLCAMKK2SGK1CDK8CHEK2
SCHEMBL3765574 0.81 MAP3K11 (0.82) AXLCAMKK2SGK1CDK8CHEK2
SCHEMBL3763777 0.81 AXL (0.76) AXLCAMKK2SGK1CDK8CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines GlaxoSmithKline, LLC 2012-09-20 US claimed
WO-2010049173-A1 USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES CENIX BIOSCIENCE GMBH (DE) 2010-05-06 WO claimed
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes GLAXOSMITHKLINE LLC 2009-09-17 US claimed
WO-2021006707-A1 USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES 한양대학교 산학협력단 2021-01-14 WO disclosed
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines GlaxoSmithKline, LLC 2012-09-20 US disclosed
WO-2010049173-A1 USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES CENIX BIOSCIENCE GMBH (DE) 2010-05-06 WO disclosed
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes GLAXOSMITHKLINE LLC 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes SGK1, SGK2, SGK3 AXL 1542/4885CAMKK2 157/4885SGK1 1/4885
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines SGK1, SGK2, SGK3 AXL 1432/4885CAMKK2 125/4885SGK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.